The most popular molecular targets for μPET imaging of melanoma and their respective ligands in preclinical studies are: (1) melanocortin 1 receptor (MC1R) and α-melanocyte-stimulating hormone (αMSH) peptide derivatives9,10; (2) melanin and benzamide-bearing pharmacophores11,12; (3) integrin αvβ3 and RGD derivatives13,14; and (4) integrin α4β1 (also known as very late antigen-4, VLA-4) and peptidomimetic ligand LLP2A derivatives15,16. Here, MC1R is linked to melanoma.